Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Best Peptides for Healing: Mechanism and Evidence Comparison

BPC-157 VEGFR2 activation → angiogenesis and endothelial cell proliferation Soft tissue (tendon, ligament, muscle), gastric ulcers, inflammatory bowel models 10 mcg/kg in animal models; human extrapolation suggests 200–500 mcg daily Strongest evidence for vasc

This comparison does not assign a generated winner or score.

  • BPC-157
  • VEGFR2 activation → angiogenesis and endothelial cell proliferation
  • Soft tissue (tendon, ligament, muscle), gastric ulcers, inflammatory bowel models
  • 10 mcg/kg in animal models; human extrapolation suggests 200–500 mcg daily
  • Strongest evidence for vascular-dependent injuries where blood supply is the limiting factor. Less relevant for avascular tissues like cartilage
  • TB-500 (Thymosin Beta-4)
  • G-actin sequestration → enhanced cell migration and tissue remodeling
  • Muscle strains, cardiac tissue post-MI, dermal wounds, corneal injuries
  • 2–6 mg per administration in equine models; human research uses 2–10 mg bi-weekly
  • Most effective during active cell migration phases. Timing relative to injury matters more than total cumulative dose
  • GHK-Cu
  • Copper-dependent collagen synthesis, MMP activation, TGF-beta1 downregulation
  • Skin wounds, post-surgical healing, hair follicle regeneration
  • 1–50 nanomolar in vitro; topical formulations use 0.05–2% concentrations
  • Dual benefit: accelerates collagen deposition while reducing scar formation. But phase-dependent, ineffective if administered too early in inflammatory phase
  • Thymalin
  • Thymus peptide bioregulator → immune modulation and T-cell function restoration
  • Immune senescence, post-infection recovery, chronic inflammation
  • 10–30 mg per course over 10 days in clinical studies
  • Not a direct tissue repair peptide. Works by restoring immune surveillance and reducing chronic inflammatory load that impairs healing
  • Dihexa
  • HGF/c-Met pathway activation → neurogenesis and synaptic plasticity
  • Cognitive decline models, neurodegenerative disease, traumatic brain injury (preclinical)
  • 0.5–5 mg/kg in rodent studies; human extrapolation unclear due to BBB permeability unknowns
  • Potent neurogenic peptide with 7-log orders more potency than BDNF in vitro. But clinical translation limited by safety data gaps